Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.

C S Ulrik

Department of Pulmonary Medicine P, Bispebjerg Hospital, Copenhagen, Denmark.

BACKGROUND--The acute response to bronchodilators in patients with chronic obstructive pulmonary disease (COPD) is modest; it has, however, been suggested that these patients may benefit from long term treatment. METHODS--To investigate the efficacy of salmeterol in smokers with moderate to severe COPD a double blind, randomised, crossover comparison was performed between salmeterol (50 micrograms twice daily) and placebo in 63 patients with stable COPD (mean age 65 years). Prior to inclusion, all patients had a forced expiratory volume in one second (FEV1) of < 60% of predicted and an improvement in FEV1 of < 15% following 400 micrograms inhaled salbutamol. Patients received four weeks of therapy with each of the treatment regimens. Assessment of efficacy was made with recording of morning and evening peak expiratory flow rates (PEF), respiratory symptoms, and use of rescue salbutamol. FEV1 was measured before and after nebulised salbutamol prior to randomisation and at the end of each treatment period. RESULTS--Morning PEF values were higher during the salmeterol than during the placebo period, although the mean treatment difference was small (12 l/min (95% confidence limits 6 to 17)). No difference in mean evening PEF values was found. Diurnal variation in PEF, assessed as the difference between the morning PEF and that of the previous evening, was more pronounced during the placebo than during the salmeterol period. The mean spirometric values (including reversibility in FEV1) obtained at the end of the two treatment periods were similar. Compared with placebo, treatment with salmeterol was associated with lower daytime and night time symptom scores and less use of rescue salbutamol both during the day and the night. The patients rated the treatment with salmeterol better than treatment with placebo. CONCLUSIONS--This study shows that, compared with placebo, treatment with salmeterol produces an improvement in respiratory symptoms and morning PEF values in patients with moderate to severe COPD. Treatment with long acting beta agonists may therefore result in an improvement in functional status, even in patients suffering from apparently nonreversible obstructive pulmonary disease.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Salmeterol in smokers with COPD.

B. J. Lipworth
Thorax 1996 51: 110. [PDF]

This article has been cited by other articles:

• Rodrigo, G. J., Nannini, L. J., Rodriguez-Roisin, R. (2008). Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review. Chest 133: 1079-1087 [Abstract] [Full Text]  
• Decramer, M. (2006). Tiotropium as essential maintenance therapy in COPD. ERR 15: 51-57 [Abstract] [Full Text]  
• van Noord, J. A., Aumann, J. L., Janssens, E., Verhaert, J., Smeets, J. J., Mueller, A., Cornelissen, P. J. G. (2006). Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPD. Chest 129: 509-517 [Abstract] [Full Text]  
• Vincken, W. (2005). Bronchodilator treatment of stable COPD: long-acting anticholinergics. ERR 14: 23-31 [Abstract] [Full Text]  
• Scala, R., Naldi, M., Archinucci, I., Coniglio, G., Nava, S. (2005). Noninvasive Positive Pressure Ventilation in Patients With Acute Exacerbations of COPD and Varying Levels of Consciousness. Chest 128: 1657-1666 [Abstract] [Full Text]  
• Vestbo, J, Pauwels, R, Anderson, J A, Jones, P, Calverley, P, on behalf of the TRISTAN study group, (2005). Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 60: 301-304 [Abstract] [Full Text]  
• Smith, B J, Appleton, S L, Veale, A J, McElroy, H J, Veljkovic, D, Saccoia, L (2004). Eformoterol n-of-1 trials in chronic obstructive pulmonary disease poorly reversible to salbutamol. Chronic Respiratory Disease 1: 63-69 [Abstract]  
• Celli, B. R. (2003). A 62-Year-Old Woman With Chronic Obstructive Pulmonary Disease. JAMA 290: 2721-2729 [Full Text]  
• MacNee, W, Calverley, P M A (2003). Chronic obstructive pulmonary disease * 7: Management of COPD. Thorax 58: 261-265 [Abstract] [Full Text]  
• Donohue, J. F., van Noord, J. A., Bateman, E. D., Langley, S. J., Lee, A., Witek, T. J. Jr, Kesten, S., Towse, L. (2002). A 6-Month, Placebo-Controlled Study Comparing Lung Function and Health Status Changes in COPD Patients Treated With Tiotropium or Salmeterol*. Chest 122: 47-55 [Abstract] [Full Text]  
• DAHL, R., GREEFHORST, L. A. P. M., NOWAK, D., NONIKOV, V., BYRNE, A. M., THOMSON, M. H., TILL, D., DELLA CIOPPA, G. (2001). Inhaled Formoterol Dry Powder Versus Ipratropium Bromide in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 164: 778-784 [Abstract] [Full Text]  
• Calverley, P.M.A. (2001). Modern treatment of chronic obstructive pulmonary disease. Eur Respir J 18: 60S-66s [Abstract] [Full Text]  
• Johnson, M., Rennard, S. (2001). Alternative Mechanisms for Long-Acting {beta}2-Adrenergic Agonists in COPD. Chest 120: 258-270 [Abstract] [Full Text]  
• ZuWallack, R. L., Mahler, D. A., Reilly, D., Church, N., Emmett, A., Rickard, K., Knobil, K. (2001). Salmeterol Plus Theophylline Combination Therapy in the Treatment of COPD. Chest 119: 1661-1670 [Abstract] [Full Text]  
• PAUWELS, R. A., BUIST, A. S., CALVERLEY, P. M. A., JENKINS, C. R., HURD, S. S. (2001). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease . NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am. J. Respir. Crit. Care Med. 163: 1256-1276 [Full Text]  
• Cazzola, M., Di Lorenzo, G., Di Perna, F., Calderaro, F., Testi, R., Centanni, S. (2000). Additive Effects of Salmeterol and Fluticasone or Theophylline in COPD. Chest 118: 1576-1581 [Abstract] [Full Text]  
• Weiner, P., Magadle, R., Berar-Yanay, N., Davidovich, A., Weiner, M. (2000). The Cumulative Effect of Long-Acting Bronchodilators, Exercise, and Inspiratory Muscle Training on the Perception of Dyspnea in Patients With Advanced COPD. Chest 118: 672-678 [Abstract] [Full Text]  
• Kerstjens, H. A M (1999). Clinical evidence: Stable chronic obstructive pulmonary disease. BMJ 319: 495-500 [Full Text]  
• Cazzola, M., Donner, C. F., Matera, M. G. (1999). Long acting beta 2 agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax 54: 730-736 [Full Text]  
• Mahler, D. A., Donohue, J. F., Barbee, R. A., Goldman, M. D., Gross, N. J., Wisniewski, M. E., Yancey, S. W., Zakes, B. A., Rickard, K. A., Anderson, W. H. (1999). Efficacy of Salmeterol Xinafoate in the Treatment of COPD. Chest 115: 957-965 [Abstract] [Full Text]